130 related articles for article (PubMed ID: 3377815)
1. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Curtin NJ; Harris AL
Biochem Pharmacol; 1988 Jun; 37(11):2113-20. PubMed ID: 3377815
[TBL] [Abstract][Full Text] [Related]
2. Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.
Curtin NJ; Newell DR; Harris AL
Biochem Pharmacol; 1989 Oct; 38(19):3281-8. PubMed ID: 2818627
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
5. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
6. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
7. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
Jackson RC; Jackman AL; Calvert AH
Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
[TBL] [Abstract][Full Text] [Related]
8. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.
Jackman AL; Taylor GA; Calvert AH; Harrap KR
Biochem Pharmacol; 1984 Oct; 33(20):3269-75. PubMed ID: 6487375
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.
Curtin NJ; Harris AL; James OF; Bassendine MF
Br J Cancer; 1986 Mar; 53(3):361-8. PubMed ID: 3008799
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase.
Rathod PK; Reshmi S
Antimicrob Agents Chemother; 1994 Mar; 38(3):476-80. PubMed ID: 8203840
[TBL] [Abstract][Full Text] [Related]
11. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
Smith PG; Marshman E; Newell DR; Curtin NJ
Br J Cancer; 2000 Feb; 82(4):924-30. PubMed ID: 10732767
[TBL] [Abstract][Full Text] [Related]
12. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.
Thomas HD; Saravanan K; Wang LZ; Lin MJ; Northen JS; Barlow H; Barton M; Newell DR; Griffin RJ; Golding BT; Curtin NJ
Mol Cancer Ther; 2009 Jul; 8(7):1828-37. PubMed ID: 19509274
[TBL] [Abstract][Full Text] [Related]
14. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
Chong LK; Tattersall MH
Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase: a target for anticancer drug design.
Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH
Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608
[TBL] [Abstract][Full Text] [Related]
16. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
17. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
Smith PG; Thomas HD; Barlow HC; Griffin RJ; Golding BT; Calvert AH; Newell DR; Curtin NJ
Clin Cancer Res; 2001 Jul; 7(7):2105-13. PubMed ID: 11448930
[TBL] [Abstract][Full Text] [Related]
19. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
20. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
